MDS-Specific Comorbidity Index (MDS-CI) Identifies Overall Survival Differences in Myelodysplastic Syndrome Patients,

医学 内科学 共病 糖尿病 骨髓增生异常综合症 人口 骨髓 环境卫生 内分泌学
作者
Massimo Breccia,Vincenzo Federico,Giuseppina Loglisci,Roberto Latagliata,Michelina Santopietro,Adriano Salaroli,Alessandra Serrao,Gioia Colafigli,Agostino Tafuri,Giuliana Alimena
出处
期刊:Blood [Elsevier BV]
卷期号:118 (21): 3793-3793 被引量:1
标识
DOI:10.1182/blood.v118.21.3793.3793
摘要

Abstract Abstract 3793 MDS-specific comorbidity index (MDS-CI) is a score reported by the Pavia group for myelodysplastic syndromes (MDS) patients. This score is a time-dependent index developed for predicting the effect of comorbidities on outcome of these subjects. We applied this score on a total of 450 MDS patients: comorbidities were recorded at the time of diagnosis and considered by medical staff for the analysis. All patients were consecutively diagnosed and followed at our institute in a period between January 1992 and December 2006. Statistical analysis was carried out using SPSS software; survival was defined as time from diagnosis to last contact or death for any cause. Median age of the whole population was 69 years (range 21–88), with a prevalence of male sex (ratio m/f 1.6). Overall, we found the presence of one or more comorbidities in 94% of the examined patients. The most common comorbidities were cardiac disorders observed in 40% of patients, followed by diabetes with organ damage recorded in 22 cases. Application of MDS-CI score identified 300 patients with score 0, 55 patients with score 1, 80 patients with score 2 and 15 patients with score >2. We found significant differences in OS according to MDS-CI stratification: from 38 months for low risk patients (score 0) to 22 months for high-risk patients (score >2, p=0.02). We then evaluated the prognostic effect of MDS-CI on patients stratified according to WPSS prognostic index. WPSS application was possible in 330 of 450 patients who entered the analysis (73%), due to cytogenetic availability of data: we identified 112 patients (34%) with very low/low risk, 137 patients (41.5%) with intermediate risk and 81 patients (24.5%) with high/very high risk. As reported by the Pavia group, we assessed prognostic relevance of comorbidities in very low/low risk WPSS patients, intermediate and high/very high-risk patients. We found in the first category a significant difference in OS stratification: from 48.5 months for patients with score 0 to 20.4 months for patients with score >2 (p=0.002). In WPSS intermediate risk we found similar significant OS difference: from 32.3 months for patients with score 0 to 18.3 months for patients with score 2 (p=0.001). Conversely, we did not find significant differences in WPSS high/very high-risk patients. We also found significant correlations between presence of comorbidities at baseline, as stratified with MDS-CI, and risk of non-leukemic death: from 22% in patients without comorbidities to 75% in patients with score >2 according to MDS-CI (p=0.002). Our analysis showed the efficacy of MDS-CI on a large series of MDS consecutively seen, diagnosed and followed in a single center while strengthening the results reported by the Pavia group: in fact, the value of comorbidities was confirmed in a cohort of patients similar to that observed in the original paper, in terms of median age (69 years in our series vs 66 years in the Pavia series), but with higher percentage of patients with intermediate WPSS risk (41.5% in our series vs 18% in the Pavia population). MDS-CI is a very valid tool capable to differentiate MDS patients with very low/low and intermediate WPSS risk in terms of OS and non-leukemic death risk. Disclosures: Alimena: Novartis: Honoraria; Bristol Myers Squibb: Honoraria.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
CodeCraft应助董啊采纳,获得10
刚刚
魔力巴啦啦完成签到 ,获得积分10
1秒前
自信雅琴发布了新的文献求助20
1秒前
1秒前
许鑫蓁完成签到 ,获得积分10
1秒前
lulu加油完成签到,获得积分10
2秒前
2秒前
xiangrikui发布了新的文献求助10
2秒前
牛马完成签到 ,获得积分10
3秒前
科研通AI5应助WJH采纳,获得10
4秒前
Zard发布了新的文献求助10
4秒前
王冉冉完成签到,获得积分10
5秒前
ryan1300完成签到 ,获得积分10
5秒前
易拉罐完成签到,获得积分10
5秒前
ZQ完成签到,获得积分10
5秒前
yyds完成签到,获得积分20
5秒前
5秒前
6秒前
彭于晏应助刘宇采纳,获得10
6秒前
7秒前
leeom发布了新的文献求助10
9秒前
Timo干物类完成签到,获得积分10
9秒前
北冥有鱼给北冥有鱼的求助进行了留言
9秒前
9秒前
王冉冉发布了新的文献求助30
9秒前
Ava应助易拉罐采纳,获得10
10秒前
隐形曼青应助无心的土豆采纳,获得10
10秒前
乐于助人大好人完成签到 ,获得积分10
10秒前
ZZQ完成签到,获得积分10
14秒前
量子星尘发布了新的文献求助10
14秒前
Lina HE完成签到 ,获得积分10
14秒前
852应助科研通管家采纳,获得10
14秒前
Ava应助科研通管家采纳,获得10
15秒前
ED应助科研通管家采纳,获得10
15秒前
领导范儿应助科研通管家采纳,获得10
15秒前
15秒前
Akim应助科研通管家采纳,获得10
15秒前
进步完成签到,获得积分10
15秒前
852应助科研通管家采纳,获得10
15秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038569
求助须知:如何正确求助?哪些是违规求助? 3576279
关于积分的说明 11374944
捐赠科研通 3305979
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892698
科研通“疑难数据库(出版商)”最低求助积分说明 815048